Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 8OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Meningeal Carcinomatosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 4Blood Specimen Collection 3Ultrasonography 2Temozolomide 2Radiosurgery 2Pemetrexed 2Exercise 2pembrolizumab 1lithium sulfate 1ipatasertib 1dactolisib 1aumolertinib 1aflutinib 1Zinc 1Surgery, Computer-Assisted 1Standard of Care 1Quality of Life 1Pliability 1Photic Stimulation 1Observation 1Neuropsychological Tests 1Moxibustion 1Metformin 1Mental Status and Dementia Tests 1Magnetic Resonance Imaging 1Lomustine 1Lithium 1Hypoglycemic Agents 1Ga(III)-DOTATOC 1Duloxetine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × aflutinib × CNS × Clear all
NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

Phase NA Recruiting
60 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡